High Barriers To Entry For Biogenerics Will Lead To Lower Cost Savings – Duke
Executive Summary
Challenges facing potential manufacturers of follow-on biologics such as a higher cost of entry and initially slower uptake will result in lower cost savings than those seen with the launch of small molecule generics, according to Duke University economist Henry Grabowski